Interferon beta in multiple sclerosis: relationship between sustained serum IgG levels and clinical outcome.
We investigated the effects of interferon beta-1a (IFN beta-1a) on specific response towards two immunodominant MBP peptides and on global production of IgG. We evaluated 54 sera from multiple sclerosis (MS) patients at baseline and 1 year after treatment. We did not observe any modification of immune response to the MBP peptides but we noted a significant decrease in mean IgG concentrations in patients with progression of the disease but not in stable patients. These results suggest that IFN beta1a restores or maintains a beneficial immune response.
Dubucquoi
S
S
Department of Immunology, CHRU of LILLE, 1 place de Verdun, 59045 cedex, Lille, France. immunologie@univ-lille2.fr
de Seze
J
J
Lefranc
D
D
Almeras
L
L
Dutoit
V
V
Prin
L
L
Vermersch
P
P
D000328:Adult; D001323:Autoantibodies / Q000097:blood / Q000187:drug effects; D018450:Disease Progression; D015536:Down-Regulation / Q000187:drug effects* / Q000276:immunology; D000939:Epitopes / Q000276:immunology; D005260:Female; D006801:Humans; D007107:Immune System / Q000187:drug effects* / Q000276:immunology; D007074:Immunoglobulin G / Q000097:blood* / Q000187:drug effects*; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000097:blood* / Q000188:drug therapy* / Q000276:immunology; D004676:Myelin Basic Protein / Q000276:immunology; D010446:Peptide Fragments / Q000276:immunology; D016896:Treatment Outcome
D001323:Autoantibodies; D000939:Epitopes; D007074:Immunoglobulin G; D004676:Myelin Basic Protein; D010446:Peptide Fragments; D016899:Interferon-beta; D000068556:Interferon beta-1a